Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Biologic therapies for psoriasis. A systematic review.

Boehncke WH, Prinz J, Gottlieb AB.

J Rheumatol. 2006 Jul;33(7):1447-51. Epub 2006 May 15. Review.

PMID:
16724367
2.

[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].

Zhang Z, Schmitt J, Wozel G, Kirch W.

Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. Epub 2009 Feb 26. German.

PMID:
19242664
3.

Advancements in the treatment of psoriasis: role of biologic agents.

Rich SJ, Bello-Quintero CE.

J Manag Care Pharm. 2004 Jul-Aug;10(4):318-25. Review.

4.

Biologic agents in the treatment of psoriasis.

Guarneri F, Guarneri C, Guarneri B.

Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):193-217. Review.

PMID:
19075983
5.

Biologic therapeutics in the treatment of psoriasis. Part 1: review.

Langley RG, Gupta AK, Cherman AM, Inniss KA.

J Cutan Med Surg. 2007 May-Jun;11(3):99-122. Review.

PMID:
17511926
6.
7.
8.

Combining traditional agents and biologics for the treatment of psoriasis.

Cather JC, Menter A.

Semin Cutan Med Surg. 2005 Mar;24(1):37-45. Review.

PMID:
15900797
9.

New biologic therapies for psoriatic disease.

Bohjanen KA, Prawer SE.

Minn Med. 2004 Mar;87(3):34-6.

PMID:
15080292
10.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Review.

PMID:
21910698
11.

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.

Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.

Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Review.

PMID:
18547300
12.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

13.

Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.

Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.

J Dermatolog Treat. 2011 Apr;22(2):65-74. doi: 10.3109/09546630903551258. Epub 2010 May 5.

PMID:
20443663
14.

Biologic survival.

Noiles K, Vender R.

J Drugs Dermatol. 2009 Apr;8(4):329-33. Review.

PMID:
19363851
15.

Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

Graves JE, Nunley K, Heffernan MP.

J Am Acad Dermatol. 2007 Jan;56(1):e55-79. Epub 2006 Nov 7. Review.

PMID:
17190618
16.

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.

Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C.

J Cutan Med Surg. 2006;9 Suppl 1:18-25. Review.

PMID:
16633860
17.

Understanding the new clinical landscape for psoriasis: a comparative review of biologics.

Sauder DN, Mamelak AJ.

J Cutan Med Surg. 2004 Jul-Aug;8(4):205-12. Review.

PMID:
16091996
18.
19.

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.

Leman J, Burden AD.

Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x. Review.

PMID:
23082811
20.

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.

Katugampola RP, Lewis VJ, Finlay AY.

Br J Dermatol. 2007 May;156(5):945-50. Epub 2007 Mar 28. Review.

PMID:
17388922
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk